Back to search results

Investigating PSMA in Metastatic Triple Negative Breast Cancer

This study is looking at how a specific protein called Prostate Specific Membrane Antigen (PSMA) shows up in people with metastatic Triple Negative Breast Cancer (TNBC). Researchers will use two types of PET scans: FDG PET/CT and Pyl PET/CT (using 18F-DCFPyL) to see if PSMA is present in cancer lesions. The goal is to see if PSMA-targeted treatments could be an option for TNBC. You may be eligible if you are a woman aged 18-90 with metastatic TNBC that shows up on an initial FDG PET/CT scan. The study aims to enroll 30 participants and will measure how well the Pyl PET/CT detects lesions compared to FDG PET/CT within 4 weeks.

Study design
This is an interventional study with a planned enrollment of 30 women. It is not specified if it is randomized or blinded.
What's involved
You would have two visits, each involving a PET imaging scan. The first scan takes about 20 minutes.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, lesion detection sensitivity, is measured at 4 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06586047

Breast Cancer PSMA PET

Recruiting
EARLY_PHASE1Ages 18–90InterventionalDiagnostic
Ahmad Shariftabrizi
~30 participants
Updated 2026-08-06 on ClinicalTrials.gov
What's tested:PET imaging

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Lesion detection sensitivity analysis
Measured over 4 weeks

Conditions

Triple Negative Breast Cancer

Explore related trials

Breast CarcinomaTriple-negative breast cancer

Where it's being run

1 sites across 1 states
Iowa1

Who to contact

Ahmad Shariftabrizi, M.D.
[email protected]
319-887-4942
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Female \>= 18 years of age
Patients in distantly metastatic TNBC based on the initial diagnosis biopsy.
Patient should have FDG positive metastatic lesions on the initial PET/CT scan performed in this study to be further included.

Exclusion

Patients with known active other malignancy.
Unable to tolerate PET/CT procedure.
Pregnant or breastfeeding.
Patients with any medical condition that might compromise the safety of subject during PET acquisitions.

What this trial measures

  • Lesion detection sensitivity analysis4 weeks

    Comparing the sensitivity of 18 F-DCFPyL-PET/CT and FDG PET/CT in metastatic lesion detection in triple-negative breast cancer patients.